model updat ad thought
speak compani
growth expect
surpris weak follow solid quarter updat
model follow earn consensu
primarili driven pharma segment well increas sale
devic
consum segment mute see pharma posit continu
drive top bottom line growth establish blockbust
imbruvica darzalex xarelto well newer product tremfya
erleada believ appreci maintain
outperform rate lower target price rel
valuat blue sky valuat grey sky valuat
ep remain increas
pleas let us know would like
updat compani model primari risk rate
target price slowdown key pharma growth driver
disappoint data on-going clinic trial import upcom clinic
catalyst includ data pipelin depress drug esketamin expect
marin
command trial xarelto result head-to-head trial
tremfya vs cosentyx psoriasi
earli may data
meet
notabl model updat rais zytiga sale given strong uptak
post latitud data still assum product go gener later
year sale need replac erleada immunolog
increas tremfya estim given rapid uptak lower remicad
estim given slightli greater biosimilar price pressur
previous model net increas franchis also lower
uptravi tracleer keep slower ramp ex-u sale
acceler impact gener respect also adjust net interest
expens incom expens oi line
compani updat guidanc full year
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow confer
call gain addit clariti dynam around certain product
well bake expect around fy summar
compani answer question
declin mostli due greater price discount
yoy declin reason assumpt rest
specif comment rebat
volum growth due brand concerta
overal impact due gener increas discount
gener
item brand concerta author gener
difficult make
formul patent april
dose regimen patent jan
month stay goe june
also difficult make
ex-u sale small forma grow due continu launch
uptak would still guid toward small
compass pdufa submit dec potenti approv dec
detail head head studi vs cosentyx
pre-specifi primari endpoint non-inferior
abil test superior secondari endpoint
base latest timelin would expect see top line result intern
like plan share publicli earli
whether press releas issu prior confer present
yet determin
ad invest capit spend
invest capit spend next year us
increas
specif year versu capit spend
sustenna/ schiz sale sale salescost expensesoper incom back incom net countpf dilut forecastgrowthgrowthvarianceep charl martineau pm univers toronto
price apr rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
us million unless otherwis state
good amort profit expens incom expens tax share continu analysisgross margin oper margin per changestot ep charl martineau pm univers toronto figur balanc sheet
us million unless otherwis state
 expens current stockhold equityloan note rebat return tax current tax relat term tax receiv employe stock liabil stockhold charl martineau pm univers toronto figur revenu statement
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
